128 related articles for article (PubMed ID: 35483449)
1. Modified dynamic risk stratification system further predicts individual outcome in patients with intermediate-risk papillary thyroid cancer.
Cuéllar DI; De Los Reyes A; Llamas-Olier A
Ann Endocrinol (Paris); 2023 Apr; 84(2):242-248. PubMed ID: 35483449
[TBL] [Abstract][Full Text] [Related]
2. Individualized Follow-Up Strategy for Patients with an Indeterminate Response to Initial Therapy for Papillary Thyroid Carcinoma.
Oh HS; Ahn JH; Song E; Han JM; Kim WG; Kim TY; Kim WB; Shong YK; Jeon MJ
Thyroid; 2019 Feb; 29(2):209-215. PubMed ID: 30384812
[TBL] [Abstract][Full Text] [Related]
3. Predictors of recurrence after total thyroidectomy in 1,611 patients with papillary thyroid carcinoma: postoperative stimulated serum thyroglobulin and ATA initial and dynamic risk assessment.
Ywata de Carvalho A; Kohler HF; Ywata de Carvalho CCG; Vartanian JG; Kowalski LP
Arch Endocrinol Metab; 2024 Apr; 68():e220506. PubMed ID: 38578436
[TBL] [Abstract][Full Text] [Related]
4. Evaluating the 2015 American Thyroid Association Risk Stratification System in High-Risk Papillary and Follicular Thyroid Cancer Patients.
van Velsen EFS; Stegenga MT; van Kemenade FJ; Kam BLR; van Ginhoven TM; Visser WE; Peeters RP
Thyroid; 2019 Aug; 29(8):1073-1079. PubMed ID: 31140385
[No Abstract] [Full Text] [Related]
5. Outcomes of patients with differentiated thyroid cancer risk-stratified according to the American thyroid association and Latin American thyroid society risk of recurrence classification systems.
Pitoia F; Bueno F; Urciuoli C; Abelleira E; Cross G; Tuttle RM
Thyroid; 2013 Nov; 23(11):1401-7. PubMed ID: 23517313
[TBL] [Abstract][Full Text] [Related]
6. Dynamic risk stratification system in post-lobectomy low-risk and intermediate-risk papillary thyroid carcinoma patients.
Cho JW; Lee YM; Lee YH; Hong SJ; Yoon JH
Clin Endocrinol (Oxf); 2018 Jul; 89(1):100-109. PubMed ID: 29672893
[TBL] [Abstract][Full Text] [Related]
7. Dynamic Risk Estimates of Outcome in Chinese Patients with Well-Differentiated Thyroid Cancer After Total Thyroidectomy and Radioactive Iodine Remnant Ablation.
Shen FC; Hsieh CJ; Huang IC; Chang YH; Wang PW
Thyroid; 2017 Apr; 27(4):531-536. PubMed ID: 28007013
[TBL] [Abstract][Full Text] [Related]
8. Estimating risk of recurrence in differentiated thyroid cancer after total thyroidectomy and radioactive iodine remnant ablation: using response to therapy variables to modify the initial risk estimates predicted by the new American Thyroid Association staging system.
Tuttle RM; Tala H; Shah J; Leboeuf R; Ghossein R; Gonen M; Brokhin M; Omry G; Fagin JA; Shaha A
Thyroid; 2010 Dec; 20(12):1341-9. PubMed ID: 21034228
[TBL] [Abstract][Full Text] [Related]
9. Implementing the Modified 2009 American Thyroid Association Risk Stratification System in Thyroid Cancer Patients with Low and Intermediate Risk of Recurrence.
Pitoia F; Jerkovich F; Urciuoli C; Schmidt A; Abelleira E; Bueno F; Cross G; Tuttle RM
Thyroid; 2015 Nov; 25(11):1235-42. PubMed ID: 26132983
[TBL] [Abstract][Full Text] [Related]
10. Predictors of incomplete response to therapy among Filipino patients with papillary thyroid cancer in a tertiary hospital.
Mendoza ES; Lopez AA; Valdez VA; Cunanan EC; Matawaran BJ; Kho SA; Sero-Gomez MH
J Endocrinol Invest; 2016 Jan; 39(1):55-62. PubMed ID: 26036600
[TBL] [Abstract][Full Text] [Related]
11. IS IT WORTH SUPPRESSING TSH IN LOW- AND INTERMEDIATE-RISK PAPILLARY THYROID CANCER PATIENTS BEFORE THE FIRST DISEASE ASSESSMENT?
Lamartina L; Montesano T; Falcone R; Biffoni M; Grani G; Maranghi M; Ciotti L; Giacomelli L; Ramundo V; Lomonaco C; Di Gioia CR; Piernatale L; Ronga G; Durante C
Endocr Pract; 2019 Feb; 25(2):165-169. PubMed ID: 30383494
[TBL] [Abstract][Full Text] [Related]
12. Dynamic Risk Stratification in Stage I Papillary Thyroid Cancer Patients Younger Than 45 Years of Age.
Sung TY; Cho JW; Lee YM; Lee YH; Kwon H; Jeon MJ; Kim WG; Choi YJ; Song DE; Chung KW; Yoon JH; Hong SJ
Thyroid; 2017 Nov; 27(11):1400-1407. PubMed ID: 28847226
[TBL] [Abstract][Full Text] [Related]
13. Initial and Dynamic Risk Stratification of Pediatric Patients With Differentiated Thyroid Cancer.
Sung TY; Jeon MJ; Lee YH; Lee YM; Kwon H; Yoon JH; Chung KW; Kim WG; Song DE; Hong SJ
J Clin Endocrinol Metab; 2017 Mar; 102(3):793-800. PubMed ID: 27809646
[TBL] [Abstract][Full Text] [Related]
14. Thyroglobulin Antibodies as a Prognostic Factor in Papillary Thyroid Carcinoma Patients with Indeterminate Response After Initial Therapy.
Landenberger GMC; de Souza Salerno ML; Golbert L; de Souza Meyer EL
Horm Metab Res; 2021 Feb; 53(2):94-99. PubMed ID: 32886943
[TBL] [Abstract][Full Text] [Related]
15. Minimal Extrathyroidal Extension in Predicting 1-Year Outcomes: A Longitudinal Multicenter Study of Low-to-Intermediate-Risk Papillary Thyroid Carcinoma (ITCO#4).
Forleo R; Grani G; Alfò M; Zilioli V; Giubbini R; Zatelli MC; Gagliardi I; Piovesan A; Ragni A; Morelli S; Puxeddu E; Pagano L; Deandrea M; Ceresini G; Torlontano M; Puligheddu B; Antonelli A; Centanni M; Fugazzola L; Spiazzi G; Monti S; Rossetto R; Monzani F; Tallini G; Crescenzi A; Sparano C; Bruno R; Repaci A; Tumino D; Pezzullo L; Lombardi CP; Ferraro Petrillo U; Filetti S; Durante C; Castagna MG
Thyroid; 2021 Dec; 31(12):1814-1821. PubMed ID: 34541894
[No Abstract] [Full Text] [Related]
16. Practical Performance of the 2015 American Thyroid Association Guidelines for Predicting Tumor Recurrence in Patients with Papillary Thyroid Cancer in South Korea.
Lee SG; Lee WK; Lee HS; Moon J; Lee CR; Kang SW; Jeong JJ; Nam KH; Chung WY; Jo YS; Lee J
Thyroid; 2017 Feb; 27(2):174-181. PubMed ID: 27750028
[TBL] [Abstract][Full Text] [Related]
17. Real-World Performance of the American Thyroid Association Risk Estimates in Predicting 1-Year Differentiated Thyroid Cancer Outcomes: A Prospective Multicenter Study of 2000 Patients.
Grani G; Zatelli MC; Alfò M; Montesano T; Torlontano M; Morelli S; Deandrea M; Antonelli A; Francese C; Ceresini G; Orlandi F; Maniglia CA; Bruno R; Monti S; Santaguida MG; Repaci A; Tallini G; Fugazzola L; Monzani F; Giubbini R; Rossetto R; Mian C; Crescenzi A; Tumino D; Pagano L; Pezzullo L; Lombardi CP; Arvat E; Petrone L; Castagna MG; Spiazzi G; Salvatore D; Meringolo D; Solaroli E; Monari F; Magri F; Triggiani V; Castello R; Piazza C; Rossi R; Ferraro Petrillo U; Filetti S; Durante C
Thyroid; 2021 Feb; 31(2):264-271. PubMed ID: 32475305
[No Abstract] [Full Text] [Related]
18. The Prospective Implementation of the 2015 ATA Guidelines and Modified ATA Recurrence Risk Stratification System for Treatment of Differentiated Thyroid Cancer in a Canadian Tertiary Care Referral Setting.
Wu J; Hu XY; Ghaznavi S; Kinnear S; Symonds CJ; Grundy P; Parkins VM; Sharma P; Lamb D; Khalil M; Hyrcza M; Chandarana SP; Pasieka JL; Harvey A; Warshawski J; Hart R; Deutschman M; Randall DR; Paschke R
Thyroid; 2022 Dec; 32(12):1509-1518. PubMed ID: 36226405
[No Abstract] [Full Text] [Related]
19. The Role of American Thyroid Association Pediatric Thyroid Cancer Risk Stratification and
Giles Şenyürek Y; İşcan Y; Sormaz İC; Poyrazoğlu Ş; Tunca F
J Clin Res Pediatr Endocrinol; 2022 Jun; 14(2):196-206. PubMed ID: 35135184
[TBL] [Abstract][Full Text] [Related]
20. Patients with Papillary Thyroid Carcinoma at Intermediate Risk of Recurrence According to American Thyroid Association Criteria Can Be Reclassified as Low Risk When the Postoperative Thyroglobulin Is Low.
Rosario PW; Furtado Mde S; Mourão GF; Calsolari MR
Thyroid; 2015 Nov; 25(11):1243-8. PubMed ID: 26359309
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]